• Investigation of common polymorphisms in squamous cell skin cancers based on age in Iranian genetic profiles and investigation of side effects of chemical drugs in chemotherapy
  • Majid mesgar tehrani,1,* Fatemeh Izadi,2 Mohammad mahdi Eslami,3 Reza Mirlohi,4
    1. Member of the Core Committee of the National Genomics Hub, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    2. Iran , Esfahan , Shahid Ashrafi esfahani university
    3. Member of the Bioinformatics Research Group, Nasim Research Institute, Tehran, Iran
    4. Member of the Bioinformatics Research Group, Nasim Research Institute, Tehran, Iran


  • Introduction: Squamous cell carcinoma of the skin is the second most common non-melanoma skin cancer worldwide, accounting for approximately 20% of all skin malignancies . Certain medications can also be associated with a higher risk of non-melanoma skin cancer .Personalized medicine tailors therapies, disease prevention, and health maintenance to the individual, with pharmacogenomics serving as a key tool to improve outcomes and prevent adverse effects
  • Methods: NCBI MEGA GENE OMIM
  • Results: To use drugs to treat squamous cell carcinoma of the skin, it is necessary to first perform genetic tests on patients to check for the presence of polymorphisms (like (A>C,G,T)rs113488022, (C>A,G,T)rs1805007,(G>A)rs3088440,…) in common genes, including BRAF, MC1R, CDKN2A before prescribing drugs and therapy, so that if polymorphisms are present, drugs with fewer side effects can be prescribed to the patient
  • Conclusion: In this article, we collect a large number of high-risk polymorphisms with high population frequency that are involved in the development of squamous cell skin cancer. We also discuss the importance of personalized medicine and the impact of existing chemotherapeutic drugs on each high-risk polymorphism.
  • Keywords: Squamous cell skin cancers, Bioinformatics, Polymorphism, Pharmacogenetics, SNP